alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3395 Norovirus serological reagents. ( a ) *Identification.* Norovirus serological reagents are devices that consist of antigens and antisera used in serological tests to detect the presence of norovirus antigens in fecal samples. These devices aid in the diagnosis of norovirus infection in the setting of an individual patient with symptoms of acute gastroenteritis when the individual patient is epidemiologically linked to other patients with symptoms of acute gastroenteritis and/or aid in the identification of norovirus as the etiology of an outbreak of acute gastroenteritis in the setting of epidemiologically linked patients with symptoms of acute gastroenteritis.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9. The special control is FDA's guidance document entitled “Class II Special Controls Guidance Document: Norovirus Serological Reagents.” See § 866.1(e) for the availability of this guidance document.
[76 FR 14274, Mar. 9, 2012, as amended at 84 FR 71800, Dec. 30, 2019]
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.4860 Light based energy source device for topical application. ( a ) *Identification.* The device emits light energy at near infrared spectrum and is applied externally to the surface of herpes simplex labialis lesions on or around the lips.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) The technical parameters of the device, including wavelength, treatment time, treatment area, energy density, spot size, and power, must be characterized.
( 2 ) The cleaning and disinfection instructions for the device must be validated.
( 3 ) The device must be demonstrated to be biocompatible.
( 4 ) Performance testing must validate electromagnetic compatibility (EMC), ocular safety, and electrical safety of the device.
( 5 ) Labeling must direct end-users to contact the device manufacturer and MedWatch if they experience any adverse events when using this device.
( 6 ) Labeling must include specific information pertinent to use of the device by the intended patient population and the treatment regimen.
( 7 ) Simulated use testing must include information from a usability, label comprehension and self-selection study to demonstrate that the device can be used by the intended patient population without any assistance.
( 8 ) Clinical data must show adequate reduction in time to healing and assess risks of redness, discomfort, burns, and blisters.
[83 FR 52969, Oct. 19, 2018]
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.3410 Ethylene oxide homopolymer and/or carboxymethylcellulose sodium denture adhesive. ( a ) *Identification.* An ethylene oxide homopolymer and/or carboxymethylcellulose sodium denture adhesive is a device containing ethylene oxide homopolymer and/or carboxymethylcellulose sodium intended to be applied to the base of a denture before the denture is inserted in a patient's mouth to improve denture retention and comfort.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 872.9.
[52 FR 30097, Aug. 12, 1987, as amended at 59 FR 63008, Dec. 7, 1994; 66 FR 38798, July 25, 2001]
<TABLE> <S> <C>

<PAGE>
 
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
QUARTERLY REPORT 10-Q AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<CIK> 0000813807
<NAME> COURTYARD BY MARRIOTT LIMITED PARTNERSHIP
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLAR
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               SEP-12-1997
<EXCHANGE-RATE>                                   1.00
<CASH>                                           8,878
<SECURITIES>                                         0
<RECEIVABLES>                                    5,512
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                15,308
<PP&E>                                         523,967
<DEPRECIATION>                               (221,382)
<TOTAL-ASSETS>                                 332,283
<CURRENT-LIABILITIES>                           27,803
<BONDS>                                        335,564
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                    (31,084)
<TOTAL-LIABILITY-AND-EQUITY>                   332,283
<SALES>                                              0
<TOTAL-REVENUES>                                68,961
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                37,727
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              17,814
<INCOME-PRETAX>                                 13,420
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                 12,473
<CHANGES>                                            0
<NET-INCOME>                                    25,893
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
        

</TABLE>
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.4670 Internal tissue marker. ( a ) *Identification.* An internal tissue marker is a prescription use device that is intended for use prior to or during general surgical procedures to demarcate selected sites on internal tissues.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) The device must be demonstrated to be biocompatible. Material names and specific designation numbers must be provided.
( 2 ) Performance testing must demonstrate that the device performs as intended to mark the tissue for which it is indicated.
( 3 ) Performance data must demonstrate the sterility of the device.
( 4 ) Performance data must support the shelf life of the device by demonstrating sterility, package integrity, device functionality, and material stability over the requested shelf life.
( 5 ) Labeling must include: ( i ) A warning that the device must not be used on a non-sterile surface prior to use internally.
( ii ) An expiration date/shelf life.
( iii ) Single use only labeling must be labeled directly on the device.
[80 FR 46486, Aug. 5, 2015]
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1365 Glutathione test system. ( a ) *Identification.* A glutathione test system is a device intended to measure glutathione (the tripeptide of glycine, cysteine, and glutamic acid) in erythrocytes (red blood cells). Glutathione measurements are used in the diagnosis and treatment of certain drug-induced hemolytic (erythrocyte destroying) anemias due to an inherited enzyme deficiency.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9
[52 FR 16122, May 1, 1987, as amended at 53 FR 21449, June 8, 1988; 66 FR 38787, July 25, 2001]
Exhibit 32.2

CERTIFICATION PURSUANT TO
SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES CODE,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant
to Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, as Chief Financial Officer of
The Timberland Company (the "Company"), does hereby certify that to the undersigned's knowledge:



| |  |  | /s/BRIAN P. MCKEONBrian P. McKeon
Chief Financial Officer
| |  |  | ---------------------------------------------------------

Date:
August 11, 2003

The
foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18,
United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.

A
signed original of this written statement, required by Section 906, has been provided to The Timberland Company and will be retained by The Timberland Company and furnished to the Securities
and Exchange Commission or its staff upon request.

---

QuickLinks
**Exhibit 10.1**

 

**Summary of 2005 Management Incentive BonusPlan**

 

On January 20, 2005, the Board of Directors of Angeion Corporationapproved the 2005 Management Incentive Bonus Plan (the “2005 Bonus Plan”).  The 2005 Bonus Plan provides for the paymentof cash compensation to eligible employees, including the Company’s executiveofficers, upon achievement of predetermined targets.  The 2005 Bonus Plan is similar to bonus plansoperated by the Company in past years and provides that bonuses will be earnedduring 2005 if Angeion achieves specified levels of (i) earnings beforeinterest, taxes, depreciation and amortization, (ii) revenues from sales ofcardiorespiratory diagnostic products, and (iii) revenues from sales of NewLeaf health and fitness products.

 

Under the 2005 Bonus Plan, Mr. Rodney A. Young, the Company’s ChiefExecutive Officer, is eligible for a bonus ranging from 21.0% of base salary ifthe threshold level is met in each of the three areas to 50.0% of base salaryif the maximum level is met in each of the three areas.  The Company’s Chief Financial Officer, DaleH. Johnson, is eligible for a bonus ranging from 10.8% of base salary if thethreshold is met in each of the three areas to36.0% of base salary if themaximum level is met in each of the three areas.

 

----
p.1 

OAR Box 1828 

Prepped by Ollie Stewart 

Document Number: 

86) ll-K- (B) -74 

Docket Number: 

A-83-27 

Printed 11/12/200811:12:51 AM Sheet 86 of 325 
P.2 

^ 

II-K-(B)-74 

COMPARISON OF ICF AND EEA METHODOLOGIES FOR CALCULATING 

CAPITAL CHARGE ANNUITY FACTORS. 

Letter from T. Hogan, EEA to R. Short, EPA:SASD. 

June 15, 1981, 

THIS INFORMATION CAN BE FOUND IN DOCKET A-79-02, ITEM 

II-K-(B)-74
# C_2014175EN.01005001.xml

| 10.6.2014 | EN | Official Journal of the European Union | C 175/50 |
| --- | --- | --- | --- |

10.6.2014

EN

Official Journal of the European Union

C 175/50

---

Action brought on 2 April 2014 — Saremar v Commission

(Case T-220/14)

2014/C 175/69

Language of the case: Italian

Parties

Parties

Applicant: Saremar — Sardegna Regionale Marittima SpA (Caglliari, Italy) (represented by: G. Roberti, G. Bellitti and I. Perego, lawyers)

Applicant:

Defendant: European Commission

Defendant:

Form of order sought

Form of order sought

The applicant claims that the General Court should:

| — | Annul, in whole or in part, the contested decision in so far as:






  — | it classified the compensation paid for public services pursuant to Regional Law No 15 of 7 August 2012 and the capital finance approved by the general meeting of Saremar’s shareholders on 15 June 2012 as State aid; |
| --- | --- | --- |

—

Annul, in whole or in part, the contested decision in so far as:

—

it classified the compensation paid for public services pursuant to Regional Law No 15 of 7 August 2012 and the capital finance approved by the general meeting of Saremar’s shareholders on 15 June 2012 as State aid;

| — | it found those measures to be incompatible with the internal market and ordered that they be recovered; |
| --- | --- |

—

it found those measures to be incompatible with the internal market and ordered that they be recovered;

| — | declare, pursuant to Article 277 TFEU, that Article 4(f) of Decision 2012/21/EU and point 9 of the European Union Framework for State aid in the form of public service compensation (2011) are unlawful and inapplicable; |
| --- | --- |

—

declare, pursuant to Article 277 TFEU, that Article 4(f) of Decision 2012/21/EU and point 9 of the European Union Framework for State aid in the form of public service compensation (2011) are unlawful and inapplicable;

| — | order the Commission to pay the costs. |
| --- | --- |

—

order the Commission to pay the costs.

Pleas in law and main arguments

Pleas in law and main arguments

The pleas in law and main arguments relied on are the same as those put forward in Case T-219/14 Regione della Sardegna v Commission.

Regione della Sardegna

Commission

---
Exhibit 99.3



  Written Statement of the Chief Executive Officer and Chief Financial Officer
                          Pursuant to 18 U.S.C. ss.1350

     Solely for the purposes of complying with 18 U.S.C. ss.1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, we, the undersigned
President and Chief Executive Officer and Vice President Law/Finance and
Secretary of Ladish Co., Inc. (the "Company"), hereby certify, based on their
knowledge, that the Quarterly Report on Form 10-Q of the Company for the quarter
ended June 30, 2003 (the "Report") fully complies with the requirements of
Section 13(a) of the Securities Exchange Act of 1934 and that information
contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Company.




/s/  Kerry L. Woody
--------------------------------------
Kerry L. Woody
President and Chief Executive Officer




/s/  Wayne E. Larsen
--------------------------------------
Wayne E. Larsen
Vice President Law/Finance & Secretary


July 25, 2003
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7321 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7321

To amend the Federal Election Campaign Act of 1971 to modernize certain 
reporting requirements for electioneering communications, and for other 
                               purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           February 13, 2024

  Mr. Morelle (for himself, Mr. Steil, and Mr. Neguse) introduced the 
     following bill; which was referred to the Committee on House 
                             Administration

_______________________________________________________________________

                                 A BILL

 
To amend the Federal Election Campaign Act of 1971 to modernize certain 
reporting requirements for electioneering communications, and for other 
                               purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Electronic Filing of Electioneering 
Communication Reports Act''.

SEC. 2. MODERNIZATION OF CERTAIN REPORTING REQUIREMENTS FOR 
              ELECTIONEERING COMMUNICATIONS.

    Section 304(a)(11)(A)(i) of the Federal Election Campaign Act of 
1971 (52 U.S.C. 30104(a)(11)(A)(i)) is amended by inserting ``or makes 
electioneering communications'' after ``expenditures''.
                                 <all>
```
§ 830.300 Devices subject to device identification data submission requirements. ( a ) *In general.* The labeler of a device must provide the information required by this subpart for each version or model required to bear a unique device identifier (UDI).
( b ) *Voluntary submission of information.* If a labeler voluntarily includes a UDI on the label of a device under § 801.40, the labeler may also voluntarily submit information concerning that device under this part.
( c ) *Exclusions.* FDA may reject or remove any device identification data where: ( 1 ) The device identifier submitted does not conform to § 830.20;
( 2 ) The information concerns a device that is neither manufactured in the United States nor in interstate commerce in the United States,
( 3 ) The information concerns a product that FDA determines is not a device or a combination product that includes a device constituent part,
( 4 ) The information concerns a device or a combination product that requires, but does not have, FDA premarket approval, licensure, or clearance;
( 5 ) A device that FDA has banned under section 516 of the Federal Food, Drug, and Cosmetic Act; or
( 6 ) FDA has suspended the accreditation of the issuing agency that operates the system used by the labeler.
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1690 Thyroid stimulating hormone test system. ( a ) *Identification.* A thyroid stimulating hormone test system is a device intended to measure thyroid stimulating hormone, also known as thyrotrophin and thyrotrophic hormone, in serum and plasma. Measurements of thyroid stimulating hormone produced by the anterior pituitary are used in the diagnosis of thyroid or pituitary disorders.
( b ) *Classification.* Class II.
# C_2015363EN.01003802.xml

| 3.11.2015 | EN | Official Journal of the European Union | C 363/38 |
| --- | --- | --- | --- |

3.11.2015

EN

Official Journal of the European Union

C 363/38

---

Judgment of the General Court of 17 September 2015 — Volkswagen v OHIM (COMPETITION)

(Case T-550/14) (1)

1

((Community trade mark - Application for the Community word mark COMPETITION - Absolute ground for refusal - No distinctive character - Article 7(1)(b) of Regulation (EC) No 207/2009))

(2015/C 363/47)

Language of the case: German

Parties

Parties

Applicant: Volkswagen AG (Wolfsburg, Germany) (represented by: U. Sander, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: M. Fischer, acting as Agent)

Defendant:

Re:

Re:

Action brought against the decision of the First Board of Appeal of OHIM of 15 May 2014 (Case R 2082/2013-1) concerning an application for registration of the word sign COMPETITION as a Community trade mark.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Volkswagen AG to pay the costs. |
| --- | --- |

2.

Orders Volkswagen AG to pay the costs.

---

(1)  OJ C 329, 22.9.2014.

1

---
39005.

#### UNITED STATES CASUALTY COMPANY *et al.*v. YOUNG.

Decided September 12, 1961.

*374*Theodore G. Frankel, Nall, Miller, Cadenhead & Dennis, B. Carl Buice,*for plaintiffs in error.

*Kermit C. Bradford,*contra.

Hall, Judge.

The only ground upon which the employer assigns error is that the evidence was insufficient to support the findings of the board and award of compensation. The only question presented is whether the record contains any evidence that the claimant’s earning capacity was diminshed. *Reeves v. Royal Indem. Co.,*73 Ga. App. 2 (35 SE2d 473); *United States Fidelity &c. Co. v. Doyle,*96 Ga. App. 745 (101 SE2d 600); *United States Fidelity &c. Co. v. Maddox,*52 Ga. App. 416 (183 SE 570); *Peninsular Life Ins. Co. v. Brand,*57 Ga. App. 526 (196 SE 264); *Maryland Cas. Co. v. Brown,*48 Ga. App. 822*375(173 SE 925). In the Workmen’s Compensation Act, “disability” means impairment of earning capacity. *Blue Bell Globe Mfg. Co. v. Baird,*61 Ga. App. 298 (6 SE2d 83); *Lumbermen’s Mut. Cas. Co. v. Cook,*69 Ga. App. 131, 136 (25 SE2d 67); *Riegel Textile Corp. v. Vinyard,*88 Ga. App. 753, 755 (77 SE2d 760). It is true, as the defendant contends, that physical disabilities other than those specified in *Code Ann.*§ 114-406, unaccompanied by impairment of earning capacity are not compensable. However, physical disability not specified in *Code Ann.*§ 114-406, resulting in total or partial loss of earning capacity, is compensable under *Code Ann.*§ 114-404 or 114-405. *Employers Liability Assurance Corp. v. Hollifield,*93 Ga. App. 51 (90 SE2d 681).

In this case there was some evidence to support an award for partial disability *(Riegel Textile Corp. v. Vinyard,*88 Ga. App. 753, supra) particularly the testimony that the claimant was no longer able to do heavy work; that he was earning a lower wage doing lighter work; and that the employer was unwilling to reemploy him because of his injury. It is noted that the employer offered no evidence to contradict this last-mentioned testimony. When there is medical testimony “to the effect that in the physician’s opinion the employee was able to return to work,” and the employee’s testimony is “to the contrary,” the evidence supports a finding of disability. *Fidelity & Cas. Co. v. King,*104 Ga. App. 261 (121 SE2d 284).

*Judgment affirmed.*

*Felton, C. J., and Bell, J., concur.*
# C_2015007EN.01005501.xml

| 12.1.2015 | EN | Official Journal of the European Union | C 7/55 |
| --- | --- | --- | --- |

12.1.2015

EN

Official Journal of the European Union

C 7/55

---

Action brought on 20 October 2014 — ZZ and Others v Commission

(Case F-113/14)

(2015/C 007/68)

Language of the case: French

Parties

Parties

Applicants: ZZ and Others (represented by: T. Bontinck and A. Guillerme, lawyers)

Applicants:

Defendant: Commission

Defendant:

Subject-matter and description of the proceedings

Subject-matter and description of the proceedings

The finding of illegality of Article 45 and Annex I of the Staff Regulations and the transitional measures relating thereto, and the annulment of decisions of the appointing authority, of both general and individual scope, relating to the promotion of the eight applicants, officials in grades AD 12 and AD 13, as part of the 2014 annual promotion exercise.

Form of order sought

Form of order sought

| — | Declare Article 45 of the Staff Regulations and Annex I as well as the transitional measures relating thereto to be illegal; |
| --- | --- |

—

Declare Article 45 of the Staff Regulations and Annex I as well as the transitional measures relating thereto to be illegal;

| — | Annul the decisions of the appointing authority, of both general and individual scope, to block any possibility of promotion for the applicants, as officials in grade AD 12 or AD 13, as part of the 2014 annual promotion exercise; |
| --- | --- |

—

Annul the decisions of the appointing authority, of both general and individual scope, to block any possibility of promotion for the applicants, as officials in grade AD 12 or AD 13, as part of the 2014 annual promotion exercise;

| — | Order the Commission to pay the costs; |
| --- | --- |

—

Order the Commission to pay the costs;

| — | In the alternative: annul the decisions of the appointing authority of both general and individual scope, to block any possibility of promotion for the applicants, as officials in grade AD 12 or AD 13, as part of the 2014 annual promotion exercise 2014; |
| --- | --- |

—

In the alternative: annul the decisions of the appointing authority of both general and individual scope, to block any possibility of promotion for the applicants, as officials in grade AD 12 or AD 13, as part of the 2014 annual promotion exercise 2014;

| — | Order the Commission to pay the costs. |
| --- | --- |

—

Order the Commission to pay the costs.

---